FGP
EW icon

Freestone Grove Partners’s Edwards Lifesciences EW Stock Holding History

Freestone Grove Partners’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.5M Buy
+171,081
New +$14.3M 0.1% 238
2025
Q3 		– Sell
-790,877
Closed -$61.9M – 764
2025
Q2 		$61.9M Sell
790,877
-83,837
-10% -$6.25M 0.47% 61
2025
Q1 		$63.4M Buy
874,714
+113,500
+15% +$8.12M 0.65% 34
2024
Q4 		$56.4M Buy
+761,214
New +$53.3M 0.69% 36

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Freestone Grove Partners's EW Position: Q2 2026 in Review

Freestone Grove Partners opened a new position in Edwards Lifesciences (EW) in Q2 2026: 171,081 shares worth $15.5M. The stake represents 0.1% of the portfolio and ranks #238 among its holdings. This is a return to the name: Freestone Grove Partners previously reported a position in EW as recently as Q2 2025.

Freestone Grove Partners first reported a position in EW in Q4 2024 and has held it in 4 quarters since. The position peaked at $63.4M in Q1 2025. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Freestone Grove Partners held 171,081 shares of Edwards Lifesciences worth $15.5M as of Q2 2026.
  • Edwards Lifesciences was a new Freestone Grove Partners position in Q2 2026.
  • Edwards Lifesciences made up 0.1% of Freestone Grove Partners's portfolio in Q2 2026, its #238 holding.
  • Freestone Grove Partners first reported a position in Edwards Lifesciences in Q4 2024 and has held it in 4 quarters since.
  • Freestone Grove Partners's Edwards Lifesciences position peaked at $63.4M in Q1 2025.
  • 1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.